Novo Nordisk Shares Surge Following Aggressive Pricing Move in India
Published on 11/12/2025 at 04:08 | Redaktion boerse-global.de
Investors have responded with strong approval to Novo Nordisk’s latest strategic maneuver in the Indian pharmaceutical market. The Danish pharmaceutical giant implemented a substantial price reduction for its weight-loss medication Wegovy, triggering a notable share price increase of approximately seven percent. This decisive action intensifies the company’s competitive stance against primary rival Eli Lilly in a critical growth market.
Effective immediately, the entry-level dose of Wegovy will be available in India for approximately €115 per month, representing a sharp 37 percent decrease from the previous cost of nearly €185. Market analysts view this timing as strategically significant, with the drug’s patent protection scheduled to expire in March 2026. Generic manufacturers are Read more...
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
